These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9504864)

  • 1. Gap junctions in health and disease.
    Dermietzel R; Hofstädter F
    Virchows Arch; 1998 Feb; 432(2):177-86. PubMed ID: 9504864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of gap junction assembly using mutated connexins detected in Charcot-Marie-Tooth X-linked disease.
    Martin PE; Mambetisaeva ET; Archer DA; George CH; Evans WH
    J Neurochem; 2000 Feb; 74(2):711-20. PubMed ID: 10646523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. X-linked Charcot-Marie-Tooth disease and connexin32.
    Fischbeck KH; Abel A; Lin GS; Scherer SS
    Ann N Y Acad Sci; 1999 Sep; 883():36-41. PubMed ID: 10586227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Learning the language of cell-cell communication through connexin channels.
    Bruzzone R
    Genome Biol; 2001; 2(11):REPORTS4027. PubMed ID: 11737941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional alterations in gap junction channels formed by mutant forms of connexin 32: evidence for loss of function as a pathogenic mechanism in the X-linked form of Charcot-Marie-Tooth disease.
    Abrams CK; Freidin MM; Verselis VK; Bennett MV; Bargiello TA
    Brain Res; 2001 May; 900(1):9-25. PubMed ID: 11325342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgenic expression of human connexin32 in myelinating Schwann cells prevents demyelination in connexin32-null mice.
    Scherer SS; Xu YT; Messing A; Willecke K; Fischbeck KH; Jeng LJ
    J Neurosci; 2005 Feb; 25(6):1550-9. PubMed ID: 15703409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of gap junctions in Charcot-Marie-Tooth disease.
    Kleopa KA
    J Neurosci; 2011 Dec; 31(49):17753-60. PubMed ID: 22159091
    [No Abstract]   [Full Text] [Related]  

  • 8. Null mutations of connexin32 in patients with X-linked Charcot-Marie-Tooth disease.
    Bruzzone R; White TW; Scherer SS; Fischbeck KH; Paul DL
    Neuron; 1994 Nov; 13(5):1253-60. PubMed ID: 7946361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New functions for gap junctions.
    Paul DL
    Curr Opin Cell Biol; 1995 Oct; 7(5):665-72. PubMed ID: 8573341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered assembly of gap junction channels caused by COOH-terminal connexin32 mutants of CMTX.
    Barrio LC; Castro C; Gómez-Hernandez JM
    Ann N Y Acad Sci; 1999 Sep; 883():526-9. PubMed ID: 10586291
    [No Abstract]   [Full Text] [Related]  

  • 11. Getting to the heart of gap junction pathology. Novartis Foundations Symposium: Gap junction-mediated intercellular signalling in health and disease. London, UK, 3-5 March 1998.
    Abdulla S
    Mol Med Today; 1998 May; 4(5):192-3. PubMed ID: 9612796
    [No Abstract]   [Full Text] [Related]  

  • 12. The gap junction communication channel.
    Kumar NM; Gilula NB
    Cell; 1996 Feb; 84(3):381-8. PubMed ID: 8608591
    [No Abstract]   [Full Text] [Related]  

  • 13. Mutations of connexin32 in Charcot-Marie-Tooth disease type X interfere with cell-to-cell communication but not cell proliferation and myelin-specific gene expression.
    Yoshimura T; Satake M; Ohnishi A; Tsutsumi Y; Fujikura Y
    J Neurosci Res; 1998 Jan; 51(2):154-61. PubMed ID: 9469569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. X-linked dominant Charcot-Marie-Tooth disease and other potential gap-junction diseases of the nervous system.
    Spray DC; Dermietzel R
    Trends Neurosci; 1995 Jun; 18(6):256-62. PubMed ID: 7570999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gap junction communication in myelinating glia.
    Nualart-Marti A; Solsona C; Fields RD
    Biochim Biophys Acta; 2013 Jan; 1828(1):69-78. PubMed ID: 22326946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic epidemiology of Charcot-Marie-Tooth disease.
    Braathen GJ
    Acta Neurol Scand Suppl; 2012; (193):iv-22. PubMed ID: 23106488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic inflammation disrupts oligodendrocyte gap junctions and induces ER stress in a model of CNS manifestations of X-linked Charcot-Marie-Tooth disease.
    Olympiou M; Sargiannidou I; Markoullis K; Karaiskos C; Kagiava A; Kyriakoudi S; Abrams CK; Kleopa KA
    Acta Neuropathol Commun; 2016 Sep; 4(1):95. PubMed ID: 27585976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies in transgenic mice indicate a loss of connexin32 function in X-linked Charcot-Marie-Tooth disease.
    Abel A; Bone LJ; Messing A; Scherer SS; Fischbeck KH
    J Neuropathol Exp Neurol; 1999 Jul; 58(7):702-10. PubMed ID: 10411340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Point mutation associated with X-linked dominant Charcot-Marie-Tooth disease impairs the P2 promoter activity of human connexin-32 gene.
    Wang HL; Wu T; Chang WT; Li AH; Chen MS; Wu CY; Fang W
    Brain Res Mol Brain Res; 2000 May; 78(1-2):146-53. PubMed ID: 10891594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Connexin 32 mutations from X-linked Charcot-Marie-Tooth disease patients: functional defects and dominant negative effects.
    Omori Y; Mesnil M; Yamasaki H
    Mol Biol Cell; 1996 Jun; 7(6):907-16. PubMed ID: 8816997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.